Towards practical prevention of type 2 diabetes

Medical Hypotheses

Volumn 54, Issue 5, 2000, Pages 786-793

  McCarty, M F ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; BIOTIN; CHROMIUM; CHROMIUM PICOLINATE; GLUCOKINASE; LINOLEIC ACID; MAGNESIUM; METFORMIN; TROGLITAZONE; UBIQUINONE;

ALCOHOL CONSUMPTION; CEREAL; DIET; DIETARY INTAKE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT;

RODENTIA;

EID: 0034112464     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1054/mehy.1999.0952     Document Type: Article

References (75)

1. Anchors M. Fluoxetine is a safer alternative to fenfluramine in the medical treatment of obesity [letter]. Arch Intern Med. 157:1997;1270.
2. Anchors, M. Safer Than Phen-Fen!, Rocklin, CA, Prima Press, 1997.
3. Astrup A., Toubro S. Thermogenic, metabolic, and cardiovascular responses to ephedrine and caffeine in man. Int J Obes Relat Metab Disord. 17:1993;S41-S43.
4. Blum K., Trachtenberg M. C., Cook D. W. Neuronutrient effects on weight loss in carbohydrate bingers: an open clinical trial. Current Therapeutic Research. 48:1990;217-233.
5. McCarty M. F. Promotion of hepatic lipid oxidation and gluconeogenesis as a strategy for appetite control. Med Hypotheses. 42:1994;215-225.
6. McCarty M. F., Gustin J. C. Pyruvate and hydroxycitrate/carnitine may synergize to promote reverse electron transport in hepatocyte mitochondria, effectively "uncoupling" the oxidation of fatty acids. Med Hypotheses. 1999.
7. Salmeron J., Manson J. E., Stampfer M. J., Colditz G. A., Wing A. L., Willett W. C. Dietary fiber, glycemic load, and risk of non-insulin-dependent diabetes mellitus in women [see comments]. JAMA. 277:1997;472-477.
8. Salmeron J., Ascherio A., Rimm E. B. Dietary fiber, glycemic load, and risk of NIDDM in men. Diabetes Care. 20:1997;545-550.
9. Truswell A. S. Glycaemic index of foods. Eur J Clin Nutr. 46:1992;S91-101.
10. Truswell A. S. Dietary fiber and health. World Rev Nutr Diet. 72:1993;148-164.
11. Foster-Powell K., Miller J. B. International tables of glycemic index. Am J Clin Nutr. 62:1995;871S-890S.
12. McCarty M. F. Point of view - a role for "nutritional insurance" supplementation in preventive medicine. Med Hypotheses. 7:1981;171-185.
13. Nadler J. L., Balon T. W., Rude R. Fiber intake and risk of developing non-insulin-dependent diabetes mellitus [letter; comment]. JAMA. 277:1997;1761-1762.
14. Colditz G. A., Manson J. E., Stampfer M. J., Rosner B., Willett W. C., Speizer F. E. Diet and risk of clinical diabetes in women. Am J Clin Nutr. 55:1992;1018-1023.
15. Kao W. H., Brancati F., Nieto J., Mo J-P., Folsom A. Serum magnesium concentration and the risk of incident NIDDM: the Atherosclerosis Risk in Communities (ARIC) Study. Diabetes. 46:1997;20A.
16. Balon T. W., Jasman A., Scott S., Meehan W. P., Rude R. K., Nadler J. L. Dietary magnesium prevents fructose-induced insulin insensitivity in rats. Hypertension. 23:1994;1036-1039.
17. Balon T. W., Gu J. L., Tokuyama Y., Jasman A. P., Nadler J. L. Magnesium supplementation reduces development of diabetes in a rat model of spontaneous NIDDM. Am J Physiol. 269:1995;E745-E752.
18. Nadler J. L., Buchanan T., Natarajan R., Antonipillai I., Bergman R., Rude R. Magnesium deficiency produces insulin resistance and increased thromboxane synthesis. Hypertension. 21:1993;1024-1029.
19. Kandeel F. R., Balon E., Scott S., Nadler J. L. Magnesium deficiency and glucose metabolism in rat adipocytes. Metabolism. 45:1996;838-843.
20. Draznin B. Cytosolic calcium and insulin resistance. Am J Kidney Dis. 21:1993;32-38.
21. Zemel M. B. Nutritional and endocrine modulation of intracellular calcium: implications in obesity, insulin resistance and hypertension. Mol Cell Biochem. 188:1998;129-136.
22. Kandeel F. R., Balon E., Scott S., Nadler J. L. Magnesium deficiency and glucose metabolism in rat adipocytes. Metabolism. 45:1996;838-843.
23. Paolisso G., Sgambato S., Pizza G., Passariello N., Varricchio M., D'Onofrio F. Improved insulin response and action by chronic magnesium administration in aged NIDDM subjects. Diabetes Care. 12:1989;265-269.
24. Nadler J. L., Malayan S., Luong H., Shaw S., Natarajan R. D., Rude R. K. Intracellular free magnesium deficiency plays a key role in increased platelet reactivity in type II diabetes mellitus [see comments]. Diabetes Care. 15:1992;835-841.
25. Eibl N., Schnack C., Schernthaner G. Magnesium supplementation in type 2 diabetes [letter]. Diabetes Care. 21:1998;2031-2032.
26. Paolisso G., Tirelli A., Coppola L. Magnesium administration reduces platelet hyperaggregability in NIDDM [letter]. Diabetes Care. 12:1989;167-168.
27. Lee Y., Hirose H., Ohneda M., Johnson J. H., McGarry J. D., Unger R. H. Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc Natl Acad Sci USA. 91:1994;10878-10882.
28. Hotamisligil G. S., Arner P., Caro J. F., Atkinson R. L., Spiegelman B. M. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 95:1995;2409-2415.
29. Kern P. A., Saghizadeh M., Ong J. M., Bosch R. J., Deem R., Simsolo R. B. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest. 95:1995;2111-2119.
30. Stampfer M. J., Colditz G. A., Willett W. C. A prospective study of moderate alcohol drinking and risk of diabetes in women. Am J Epidemiol. 128:1988;549-558.
31. Rimm E. B., Chan J., Stampfer M. J., Colditz G. A., Willett W. C. Prospective study of cigarette smoking, alcohol use, and the risk of diabetes in men [see comments]. BMJ. 310:1995;555-559.
32. Colditz G. A., Giovannucci E., Rimm E. B. Alcohol intake in relation to diet and obesity in women and men [see comments]. Am J Clin Nutr. 54:1991;49-55.
33. McCarty M. F. The insulin-sensitizing activity of moderate alcohol consumption may promote leanness in women. Med Hypotheses. 1999.
34. Facchini F., Chen Y. D., Reaven G. M. Light-to-moderate alcohol intake is associated with enhanced insulin sensitivity. Diabetes Care. 17:1994;115-119.
35. Kiechl S., Willeit J., Poewe W. Insulin sensitivity and regular alcohol consumption: large, prospective, cross sectional population study (Bruneck study) [see comments]. BMJ. 313:1996;1040-1044.
36. Lazarus R., Sparrow D., Weiss S. T. Alcohol intake and insulin levels. The Normative Aging Study. Am J Epidemiol. 145:1997;909-916.
37. Prentice A. M. Alcohol and obesity. Int J Obes Relat Metab Disord. 19:1995;S44-S50.
38. Stampfer M. J., Colditz G. A., Willett W. C., Speizer F. E., Hennekens C. H. A prospective study of moderate alcohol consumption and the risk of coronary disease and stroke in women. N Engl J Med. 319:1988;267-273.
39. Fuchs C. S., Stampfer M. J., Colditz G. A. Alcohol consumption and mortality among women [see comments] [published erratum appears in. N Engl J Med. 336:1997;523.
40. Thun M. J., Peto R., Lopez A. D. Alcohol consumption and mortality among middle-aged and elderly U.S. adults [see comments]. N Engl J Med. 337:1997;1705-1714.
41. Simons L. A., Von Konigsmark M., Balasubramaniam S. What dose of vitamin E is required to reduce susceptibility of LDL to oxidation? Aust N Z J Med. 26:1996;496-503.
42. Smith-Warner S. A., Spiegelman D., Yaun S. S. Alcohol and breast cancer in women: a pooled analysis of cohort studies [see comments]. JAMA. 279:1998;535-540.
43. Sherman L., Glennon J. A., Brech W. J., Klomberg G. H., Gordon E. S. Failure of trivalent chromium to improve hyperglycemia in diabetes mellitus. Metabolism. 17:1968;439-442.
44. Abraham A. S., Brooks B. A., Eylath U. The effects of chromium supplementation on serum glucose and lipids in patients with and without non-insulin-dependent diabetes. Metabolism. 41:1992;768-771.
45. Uusitupa M. I., Mykkanen L., Siitonen O. Chromium supplementation in impaired glucose tolerance of elderly: effects on blood glucose, plasma insulin, C-peptide and lipid levels. Br J Nutr. 68:1992;209-216.
46. Anderson R. A., Cheng N., Bryden N. A., Polansky M. M., Chi J., Feng J. Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes. 46:1997;1786-1791.
47. Cheng, N. Zhu, X. Shi, H. Chromium supplementation of people with type 2 diabetes in China: a follow-up study. Anderson, R. A. International Symposium on the Health Effects of Dietary Chromium: Abstract Book. Dedham, MA, 1999, 5.
48. Cefalu W. T., Bell-Farrow A. D., Wang Z. Q. The effect of chromium supplementation on carbohydrate metabolism and body composition. Diabetes. 46:1997;55A.
49. Evans G. W., Pouchnik D. J. Composition and biological activity of chromium-pyridine carboxylate complexes. J Inorg Biochem. 49:1993;177-187.
50. Evans G. W., Bowman T. D. Chromium picolinate increases membrane fluidity and rate of insulin internalization. J Inorg Biochem. 46:1992;243-250.
51. Anderson R. A., Brantner J. H., Polansky M. M. An improved assay for biologically active chromium. Journal of Agricultural Food Chemicals. 26:1978;1219-1221.
52. Anderson R. A., Bryden N. A., Polansky M. M. Lack of toxicity of chromium chloride and chromium picolinate in rats. J Am Coll Nutr. 16:1997;273-279.
53. McCarty M. F. Subtoxic intracellular trivalent chromium is not mutagenic: implications for safety of chromium supplementation. Med Hypotheses. 49:1997;263-269.
54. Stearns D. M., Wise J. P. S., Patierno S. R., Wetterhahn K. E. Chromium (III) picolinate produces chromosome damage in Chinese hamster ovary cells. FASEB J. 9:1995;1643-1648.
55. McCarty M. F. Chromium (III) picolinate [letter] [published erratum appears in FASEB J 1996;10 (5):660]. FASEB J. 10:1996;365-369.
56. McCarty M. F. High-dose biotin, an inducer of glucokinase expression, may synergize with chromium picolinate to enable a definitive nutritional therapy of type II diabetes. Med Hypotheses. 1999.
57. Vesely D. L. Biotin enhances guanylate cyclase activity. Science. 216:1982;1329-1330.
58. Spence J. T., Koudelka A. P. Effects of biotin upon the intracellular level of cGMP and the activity of glucokinase in cultured rat hepatocytes. J Biol Chem. 259:1984;6393-6396.
59. Caro J. F., Triester S., Patel V. K., Tapscott E. B., Frazier N. L., Dohm G. L. Liver glucokinase: decreased activity in patients with type II diabetes. Horm Metab Res. 27:1995;19-22.
60. Chauhan J., Dakshinamurti K. Transcriptional regulation of the glucokinase gene by biotin in starved rats. J Biol Chem. 266:1991;10035-10038.
61. Nutr Rev. 42:1984;360-361.
62. Nutr Rev. 28:1970;242-244.
63. Reddi A., DeAngelis B., Frank O., Lasker N., Baker H. Biotin supplementation improves glucose and insulin tolerance in genetically diabetic KK mice. Life Sci. 42:1988;1323-1330.
64. Zhang H., Osada K., Maebashi M., Ito M., Komai M., Furukawa Y. A high biotin diet improves the impaired glucose tolerance of long-term spontaneously hyperglycemic rats with non-insulin-dependent diabetes mellitus. J Nutr Sci Vitaminol (Tokyo). 42:1996;517-526.
65. Zhang H., Osada K., Sone H., Furukawa Y. Biotin administration improves the impaired glucose tolerance of streptozotocin-induced diabetic Wistar rats. J Nutr Sci Vitaminol (Tokyo). 43:1997;271-280.
66. Maebashi M., Makino Y., Furukawa Y. Therapeutic evaluation of the effect of biotin on hyperglycemia in patients with non-insulin-dependent diabetes mellitus. J Clin Biochem Nutr. 14:1993;211-218.
67. Coggeshall J. C., Heggers J. P., Robson M. C., Baker H. Biotin status and plasma glucose in diabetics. Ann NY Acad Sci. 447:1985;387-392.
68. Werbach M. R. Nutritional Influences on Illness, 2nd edn. 1993;Third Line Press, Tarzana, CA.
69. McCarty M. F. Can correction of sub-optimal coenzyme Q status improve beta cell function in type II diabetics? Med Hypotheses. 1999.
70. Peraldi P., Xu M., Spiegelman B. M. Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling. J Clin Invest. 100:1997;1863-1869.
71. Komers R., Vrana A. Thiazolidinediones - tools for the research of metabolic syndrome X. Physiol Res. 47:1998;215-225.
72. Subramaniam S. The emerging role of thiazolidinediones in the treatment of diabetes-mellitus and related disorders [In Process Citation]. Clin Exp Hypertens. 21:1999;121-136.
73. Belury M. A. Conjugated dienoic linoleate: a polyunsaturated fatty acid with unique chemoprotective properties. Nutr Rev. 53:1995;83-89.
74. Houseknecht K. L., Vanden Heuvel J. P., Moya-Camarena S. Y. Dietary conjugated linoleic acid normalizes impaired glucose tolerance in the Zucker diabetic fatty fa/fa rat [published erratum appears in. Biochem Biophys Res Commun. 247:1998;911.
75. Chou P., Li C. L., Kuo H. S., Hsiao K. J., Tsai S. T. Comparison of the prevalence in two diabetes surveys in Pu-Li, Taiwan, 1987-1988 and 1991-1992. Diabetes Res Clin Pract. 38:1997;61-67.